comparemela.com
Home
Live Updates
Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication : comparemela.com
Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication
/PRNewswire/ -- The product of Fosun Kite Biotechnology Co., Ltd., jointly established by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Kite Pharma of...
Related Keywords
China
,
United States
,
Shanghai
,
Huang Hai
,
Jiangsu
,
Chinese
,
American
,
Mei Jingping
,
Fosun Kate
,
Mert Aktar
,
Ma Jun
,
Fosun Kite Biotechnology Co Ltd
,
Fosun Pharmaceutical Group
,
Drug Administration
,
Shanghai Fosun Pharmaceutical Group Co Ltd
,
Harbin Institute Of Hematology
,
Shanghai Fosun Pharmaceutical
,
Kite Pharma
,
State Drug Administration
,
Harbin Institute
,
Fosun Kite
,
England Journal
,
Fosun Pharmaceutical
,
Fosun Kite Biotechnology Co
,
Td
,
comparemela.com © 2020. All Rights Reserved.